<DOC>
	<DOCNO>NCT01068041</DOCNO>
	<brief_summary>The primary objective clinical study evaluate effectiveness safety PH3 patient diabetic nephropathy . The secondary objective identify optimal dosage subsequent study provide basis next confirmatory study study design , endpoint , study methodology .</brief_summary>
	<brief_title>Effects PH3 Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>1 . Males Females 18 70 year age type 1 type 2 diabetes 2 . Sitting blood pressure &lt; =140/90 mm Hg 3 . Serum creatinine &lt; =2.0 mg/dL 4 . Urinary albumin : creatinine ratio 30 mg/g 1000 mg/g creatinine ( first urine sample day ) 5 . Hemoglobin A1c &lt; =8 % 6 . Women childbearing potential must test negative pregnancy test take contraception measure prevent pregnancy breastfeed 7 . Voluntary write consent participate study 1 . History major cardiovascular cerebrovascular event within 6 month prior screen 2 . History cancer 3 . Receiving chronic nonsteroidal antiinflammatory therapy 4 . History diabetic ketoacidosis 5 . Has clinically significant deviation normal physical examination finding , principal investigator 's judgment , may interfere study evaluation affect subject safety 6 . Has participate investigational trial within 28 day prior study enrollment 7 . Has take herbal medical treatment prescription medication and/or overthe counter medication , within 28 day prior study enrollment . 8 . Has know allergy study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>